Bioinformatics Wary of Bust, Biopharma Spends Dollars More Wisely | GenomeWeb

The lessons of bioinformatics’ recent boom and bust cycle have not been lost on Rainer Fuchs, vice president of research informatics and operations at Biogen Idec.

Fuchs, who spoke at Bio-IT World’s and Cambridge Healthtech Institute’s inaugural Bridging Discovery and IT conference in Philadelphia in late September, said that he’s “seeing a shift from lofty expectations” about what bioinformatics can accomplish “to more realistic, smaller projects with a better [return on investment].”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.